Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.

Trigriluzole (BHV-4157) is a novel glutamate modulator for the treatment of mild-to-moderate Alzheimer’s disease (AD).

Trilostane(Win 24540; Modrastane) is an inhibitor of 3 β-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome.

TRIM24 inhibitor X is a potent TRIM24 bromodomain inhibitor for synthesis dTRIM24..

Trimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent , which improves myocardial glucose utilization through inhibition of fatty acid metabolism.

Trimethoprim 3-oxide (Trimethoprim 3-N-oxide) is the primary metabolite of trimethoprim.

Triphenyl compound A (TPh A) is a small-molecule inhibitor of nuclear protein Pirin with Kd of 0.6 uM, inhibits the interaction between pirin and Bcl3 in vitro and in cells.

Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH), shows greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion..

TrkA inhibitor compound 23 is an allosteric, potent, Subtype Selective and Peripherally Restricted TrkA Kinase Inhibitor， with IC50 of 10 nM, 180-fold selective over TrkB and 70-fold selective over TrkC in cell based assays.

Trk-IN-3 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 8.4 nM, 6.2 nM and 2.2 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.

Trk-IN-4 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.

TRO 40303 is a novel cardioprotective compound that delays mitochondrial permeability transition pore (mPTP) opening, binds specifically to TSPO at the cholesterol site (Ki=150 nM).

Trofinetide (NNZ-2566) is an analog of a molecule which is derived from IGF-1 and occurs naturally in the brain. IGF-1 is a growth factor stimulated by growth hormone.

Trospium Chloride is a competitive muscarinic cholinergic receptor antagonist.

Trovirdine inhibits HIV-1 RT with an IC50 of 7 nM when employing heteropolymeric primer/template (oligo-DNA/ribosomal RNA)and dGTP as substrate.

Troxipide is a novel gastro protective agent with antiulcer, anti-inflammatory and mucus secreting properties.

TRPM4 inhibitor 5 is a potent and selective inhibitor of TRPM4 with IC50 of 1.5 uM (Na+ influx).

TRX-818 sodium (Foslinanib sodium ) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation.

TTGM 5826 (TTGM5826, TTGM-5826) is a small molecule, potential modulator of tissue transglutaminase (tTG) conformation.

TTK21 (CBP-p300 activator TTK21) is a small molecule activator of CBP/p300 histone acetyltransferase activity with a maximal effect at a concentration of 275 uM.

TTNPB (Arotinoid Acid) is a potent RAR agonist, and inhibits binding of [3H]tRA with IC50 of 5.1 nM, 4.5 nM, and 9.3 nM for human RARα, β, and γ, respectively.

TTP 22 is a high affinity, ATP-competitive casein kinase 2 (CK2) inhibitor with IC50/Ki of 0.1 uM/40 nM; shows selectivity for CK2 over JNK3, ROCK1, and MET(IC50> 10 uM).

TTP399 (TTP-399) is a hepatoselective, oral Glucokinase (GK) activator with EC50 of 304 nM and 762 nM for human GK at high glucose concentration (15 mM) and normoglycemia (5 mM), respectively.

TTP-8307 is a potent inhibitor of the replication of several Rhinoviruses and Enteroviruses, targets the nonstructural protein 3A, inhibits the replication of coxsackievirus B3 (CVB3 Nancy) with EC50 of 1.2 uM.

Tubulin inhibitor 1 is a tubulin inhibitor, occupying the colchicine binding site, inhibits tubulin polymerization. Tubulin inhibitor 1 shows potent anti-tumor activity, casues cellular mitotic arrest in the G2/M phase, and induces cellular apoptosis.

Tubuloside A is a phenylethanoid glycoside with antioxidative effect and hepatoprotective activity.

Tubulysin A is a novel antibiotic, which is anti-microtubule, anti-mitotic, an apoptosis inducer, anticancer, anti-angiogenic, and antiproliferative.

Tubulysin B is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

TUG-1375 (TUG1375, TUG 1375) is a potent, selective free fatty acid receptor 2 (FFA2/GPR43) agonist with β-arrestin-2 pEC50 of 6.1 and cAMP pEC50 of 7.11.

TUG-770 is a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist with EC50 of 6 nM for hFFA1.

Tulathromycin is a new semi-synthetic member of the macrolide group of antibiotics that is recommended for treatment and prevention of bacterial respiratory disease in cattle and pigs.

Tulrampator (CX-1632) is an orally bioavailable positive AMPAR (allosteric modulator of AMPA receptor). Antidepressant.

TVB-3166 is an orally-available, reversible, potent, and selective fatty acid synthase (FASN) inhibitor with biochemical IC50 of 42 nM.

TVP1022 is the S-isomer of rasagiline, which is an anti-Parkinson drug, appears to have the same neuroprotective activity as the R-isomer, but is 1000-fold less active as an MAO-B inhibitor.

Twincretin(Y3298176) is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist

TX1-85-1 is a potent, selective, ATP-competitive Her3 (ErbB3) inhibitor with IC50 of 23 nM, forms a covalent bond with Cys721 located in the ATP-binding site of Her3.

TX2-121-1 is a bivalent hydrophobically tagged adamantane derivative of TX1-85-1, a potent, selective, ATP-competitive Her3 (ErbB3) inhibitor.

TY-52156 is a potent and selective inhibitor of S1P3 receptor (Ki=110 nM).

Tyclopyrazoflor is an anthranilamide compound with pesticidal activity.

TYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM, exhibits excellent selectivity (35-fold for JAK1 and 83-fold for JAK3).

Tyroserleutide is a tripeptide consisting of tyrosine, serine, and leucine with potential antineoplastic activity.

Tyrphostin AG 528 is an inhibitor of EGFR and ErbB2 with IC50s of 4.9 and 2.1 μM, respectively.

Tyrphostin AG 555 is a potent epidermal growth factor receptor kinase inhibitor.

U 19963 is a bioactive compound.

U-0126 is a selective MAP Kinase Kinase inhibitor, displaying a preference for MEK-1 (IC50 = 72 nM) and MEK-2 (IC50 58nM).

U18666A, a cell permeable drug, is a cholesterol synthesis and transport inhibitor.

UAMC00039 dihydrochloride is a potent inhibitor of dipeptidyl peptidase II (DPP-II) (IC50 = 0.48 nM).

UBCS039 is the first synthetic, specific Sirtuin 6 (SIRT6) activator, inducing autophagy in human tumor cells, with an EC50 of 38 μM.

UBE2M-DCN1 inhibitor 52 is a highly potent inhibitor of DCN1-UBE2M protein-protein interaction with IC50 of 60 nM, inhibits cullin neddylation in pulse-chase NEDD8 transfer assay with EC50 of 80 nM.

Bestatin is a natural, broad-spectrum, and competitive aminopeptidase inhibitor.

UBP 296 (UBP296, UBP-296) is a potent, and selective GluR5-subunit containing kainate receptor antagonist with Kd of 1.09 uM.

Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine..

UC-112 is a novel IAP inhibitor that potently inhibits human melanoma (A375 and M14) and human prostate (PC-3 and DU145) cancer cell lines with IC50 of 0.7-3.4 uM.

UC-1728 is a potent rabbit soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 2 nM on rabbit liver.

UC-514321 is a more effective analog of NSC-370284 that directly binds to STAT3/5, significantly and selectively suppresses the viability of AML cells with high level of TET1 expression both in vitro and in vivo.

UCN-01 (7-Hydroxystaurosporine.

UCPH-102 is a selective, brain penetrant inhibitor of EAAT1 (Excitatory amino acid transporter 1) with IC50 of 420 nM.

UCS15A is a small moelcule SH3 domain-mediated protein-protein interaction blocking agent that inhibits proline-rich ligand-mediated protein-protein interactions (PLPI).

UK 356618 is a potent and selective MMP3 inhibitor with IC50 of 5.9 nM, shows >140-fold less potent against MMP-1 (IC50=51000 nM), MMP-2 (IC50=1790 nM), MMP-9 (IC50=840 nM) and MMP-14 (IC50=1900 nM).

UK-369003 (Gisadenafil besylate) is a novel, potent, selective, orally bioavailable PDE5 inhibitor with IC50 of 1.23 nM, displays 117-fold selectivity over PDE6.

UK-371804 is a potent and selective uPA inhibitor with excellent enzyme potency (Ki 10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin).

UK-383367 (UK 383367) is a potent and selective inhibitor of BMP-1 (procollagen C-proteinase) with IC50 of 44 nM; Selective for BMP-1 over MMPs 1, 2, 3, 9 and 14 (IC50 values are >10,000 nM for listed MMPs).

UK-396082 is a potent and selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (activated TAFI.

UK5099 is an inhibitor of plasma membrane monocarboxylate transporters (MCTs) and the mitochondrial pyruvate carrier (MPC).

UKH-1114 (UKH1114) is a potent, sigma 2 receptor/Tmem97 agonist with Ki of 46 nM.

Ulinastatin (UTI) is a urinary trypsin inhibitor extracted and purified from urine of males.

Ulipristal is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure.

Ulixertinib, also known as BVD-523 and VRT752271, is an inhibitors of ERK protein kinase.

ULK-100 (ULK100) is a potent and selective ULK1 inhibitor with in vitro IC50 of 1.6 nM, inhibits ULK2 with IC50 of 2.6 nM.

ULK-101 is a potent and selective ULK1 inhibitor with in vitro IC50 of 8.3 nM.

ULK1-IN-1 highly potent ULK1 inhibitor with IC50 of 8 nM, with no enough selectivity but sufficient potency, a cellular probe of autophagy..

UNBS5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers; the mean antiproliferative activity IC50 value is 17.9 uM for 9 cancer cell lines; hydrolysis product of UNBS3157.

UNC 669 is a potent antagonist of L3MBTL1(IC50=4.2 uM) and L3MBTL3(IC50=3.1 uM).

UNC0379 is a selective, +N2106:AC2106substrate-competitive inhibitor of lysine methyltransferase SETD8 with IC50 of 7.3 uM, displays good selectivity over 15 other methyltransferases, including G9a and GLP (IC50>100 uM).

UNC-0631 is a novel G9a inhibitor with excellent potency in a variety of cell lines and excellent separation of functional potency versus cell toxicity.

UNC0642 is a novel highly potent, selective and cell permeable inhibitor of the homologous protein lysine methyltransferases, G9a and GLP, with IC50 < 2.5 nM.

UNC0646 is a potent and selective inhibitor of the homologous protein lysine methyltransferases, G9a and GLP (IC50 values are 6 nM and 15 nM for G9a and GLP, respectively).

UNC-1062 is a potent and selective Mer kinase inhibitor with IC50 of 1.1 nM, Ki of 0.33 nM.

UNC119-Src interaction inhibitor 3 is a potent, specific small molecule inhibitor of UNC119-Src interaction with IC50 of 12 nM for displacement of the Src peptide from UNC119A.

UNC1666 is a potent, specific dual Mer and Flt3 tyrosine kinase inhibitor with IC50 of 0.55 and 0.69 nM.

UNC1999 is a potent, orally bioavailable and selective inhibitor of EZH2 and EZH1 with IC50 of 2 nM and 45 nM, respectively.

UNC-2170 is a small molecule ligand for the methyl-lysine binding protein 53BP1 (p53-binding protein 1) with Kd of 22 uM against the 53BP1 tandem tudor domain.

UNC2250 is a potent and selective Mer inhibitor with IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.

UNC2881 is a potent and specific Mer kinase inhibitor; inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM.

UNC4203 (UNC-4203) is a potent, highly selective MerTK with IC50 of 2.4 nM, displays >30- and 4 -foldfold selectivity over Alx (IC50=80 nM) and Tyro3 (IC50=9.1 nM).

UNC-926 is a methyl-lysine (Kme) reader domain inhibitor; inhibits L3MBTL1 with an IC50 of 3.9 μM.

UPCDC30245 is an allosteric inhibitor of AAA ATPase p97 with IC50 of 27 nM, binds at the junction between the D1 and D2 domains of p97..

UPC-K-005 is a novel p38 inhibitor, exhibiting a IC50 of 13 μM.

UPF1854 is a potent tankyrase inhibitor with IC50 of 12 nM and 200 nM for TNKS1 and TNKS-2 respectively, displays no cross-reactivity versus other PARP proteins.

UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.

Uprosertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity.

URB754 is reported to be a potent, noncompetitive inhibitor of monoacylglycerol lipase (MAGL), exhibiting an IC50 of 200 nM for the recombinant rat brain enzyme.

Uridine 5'-monophosphate is a nucleotide that is used as a monomer in RNA.

Uridine-5'-triphosphate (UTP) is a pyrimidine nucleoside triphosphate and a substrate for the synthesis of RNA during transcription.

Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified to remove various proteins and other substances.

UR-PI376 is a potent, selective histamine H4 receptor (hH4R) agonist with pEC50 of 7.47, shows negligible hH1R and hH2R activities and significant selectivity over the hH3R..

Ursocholic acid, a bile acid found predominantly in bile of mammals, is an inhibitor of 7α-hydroxysteroid dehydrogenase and hepatocyte nuclear factor 1α.

USP10-IN-3 is a HBX19818 analog, potent and selective USP10 inhibitor, but does not inhibit USP7 (IC50>100 uM).

USP10-IN-9 is a HBX19818 analog, selective USP10 inhibitor with IC50 similar to HBX19818, but does not inhibit USP7 (IC50>100 uM)..

UTL-5g (GBL-5g) is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity.

UU-T01 is a novel small-molecule inhibitor of β-catenin/Tcf4 protein-protein interaction with Ki of 3.14 uM, binds to β-catenin with Kd of 0.531 uM..

UU-T03 is the ethyl ester derivative of UU-T02, which is a potent, selective inhibitor of β-catenin/Tcf4 interaction with Ki of 1.36 uM; exhibits growth inhibition of SW480 cells with IC50 of 10.77 uM; downregulates the transcription of AXIN2, LGR5, cyclin D1, and c-Myc in dose-dependent manners in SW480 cells.

UVI 3003 is a highly selective antagonist of retinoid X receptor (RXR), and inhibits xenopus and human RXRα in Cos7 cells, with IC50s of 0.22 and 0.24 μM, respectively.

V-11-0711 (V-11 0711) is a novel potent and selective choline kinase alpha (ChoKα) inhibitor with IC50 of 20 nM, with 11 fold less activity against ChoKβ.

V-116517 is a novel potent, selective, oral bioavailable TRPV1 antagonist with IC50 of 35.1 nM.

V-9302 is a competitive antagonist of transmembrane glutamine flux, selectively and potently targeting the amino acid transporter ASCT2.

VA-012 is a potent, selective 5-HT2C receptor positive allosteric modulator (PAM) that exhibits dose-dependent potentiation of 5-HT efficacy with EC50 of 16 nM.

Valacyclovir is an antiviral agent that acts as a very potent inhibitor of viral DNA polymerase.

Valategrast hydrochloride is a potent, α4β1 (VLA-4) and α4β7 dual antagonist..

Valbenazine(NBI-98854) is a potent and selective VMAT2 inhibitor..

Val-cit-PAB-OH is a peptide prodrug linker.

Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines.

Valganciclovir (hydrochloride), the L-valyl ester of ganciclovir, is actually a prodrug for ganciclovir.

Valrocemide (TV1901,VGD)) has a broad spectrum of anticonvulsant activity and promising potential as a new AED.

Valrubicin (AD-32) is a chemotherapy drug used to treat bladder cancer.

Vamorolone (VBP-15) is a dissociative steroidal compound, reduces NF-κB-mediated cytokine expression in vitro, alsp reduecs glucocorticoid-mediated side-effects when compared to dexamethasone in vivo.

Vanoxerine (GBR-12909, I-893, Boxeprazine) is a highly potent inhibitor of dopamine uptake in vitro in tissue slices obtained from rat neostriatum with IC50 of 40-50 nM, also inhibits norepinephrine uptake with IC50 of 560-2600 nM.

Vapendavir (BTA798) is a novel potent enteroviral capsid binder, inhibits EV71 replication of all isolates with mean EC50 of 0.7 uM.

Vapreotide acetate is a synthetic analog of somatostatin for the treatment of variceal bleeding; also exhibits antitumor activity.

Varenicline Hcl(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.

Varenicline Tartrate(CP 526555;Champix) is a nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.

Varenicline(CP 526555;Champix) is a selective α4β2 nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.

VB-82252 is a highly potent, orally active inhibitor of C. difficile toxins TcdA and TcdB, potently inhibits UDP glucose hydrolysis activity of TcdB (IC50=32 nM).

VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection.

VCMMAE-(PEG)4-DBCO is made by MMAE conjugated to DBCO-(PEG)4-vc-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

VDR 4-1 is a novel non-steroidal, small-molecule agonist of vitamin D receptor (VDR).

VE-822 is a selective ATR inhibitor with an Ki value of 0.2 nM, >150 fold selectivity over ATM (Ki=34 nM), DNA-PK (Ki >4 uM) and mTOR (Ki >1 uM).

Vecabrutinib (SNS-062) is a potent, reversible, non-covalent BTK inhibitor with IC50 of 2.9 and 4.4 nM for WT BTK and C481S BTK, respectively.

Vecuronium Bromide

VEL-0230 (NC-2300) is a potent, selective cysteine Cathepsins inhibitor with IC50 of 284, 34.5 and 186 nM for Cat B, K and S, respectively.

Velaresol, also known as BW12C or BW12C79, is a oxyhaemoglobin stabilizer.

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.

Velusetrag (TD-5108) is a potent, selective and oral 5-HT4 receptor agonist with pKi of 7.7, shows >500-fold selectivity over other 5-HT receptors.

Venlafaxine Hydrochloride is a dual ST and SLC6A2 (serotonin and noradrenalin re-uptake) inhibitor that displays ~ 30-fold higher affinity for ST (SERT) (Ki = 82 nm) than SLC6A2 (NET) (Ki = 2480 nM).

Verapamil Hcl is an L-type calcium channel blocker of the phenylalkylamine class.

Verapamil is a CYP3A inhibitor.

Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.

Verdiperstat is a selective, irreversible and orally active myeloperoxidase inhibitor, with an IC50 of 630 nM, and is used in the research of neurodegenerative brain disorders.

Vericiguat (BAY 1021189) is a novel potent, selective, orally available soluble guanylate cyclase (sGC) stimulator (MEC=0.3 uM), stimulating sGC NO-independently and in synergy with NO.

Vernakalant Hcl(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.

Verucerfont(GSK561679) is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively.

Vestipitant (GW597599) is a potent, selective, orally active NK1 receptor antagonist with pKi of 9.65.

Vestipitant (GW597599) is a potent, selective, orally active NK1 receptor antagonist with pKi of 9.65.

VGSC blocker 1 is a potent, small molecule blocker of neonatal isoform of the VGSC subtype, Nav1.5 (nNav1.5), blocks INa peak currents 34.9% at 1 uM.

VGTI-A3-03 is a novel potent, highly virus-specific inhibitor of DENV replication with greatest activity against DENV serotype 2 (IC50=25 nM), directly bind DENV capsid protein.

VGX-1027(GIT27) is an isoxazole compound that exhibits various immunomodulatory properties; reduce the secretion of IL-1beta, TNF-alpha and IL-10 from purified murine macrophages.

VHL ligand 1 TFA is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein.

VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader.

VHL-alkyne is a VHL ligand for PROTAC synthesis..

VHL-IN-15 is a potent (IC50=4.1 uM) von Hippel–Lindau protein (VHL) ligand that disrupts the VHL/HIF-1α interaction..

Vidarabine (Vira-A)

Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.

Vilanterol trifenatate (GW642444)is a novel, inhaled, long-acting β(2) agonist with inherent 24-h activity under development as a once-daily combination therapy with an inhaled corticosteroid for COPD and asthma.

Vilaprisan (BAY 1002670) is a highly potent and selective progesterone receptor (PR) modulator.

Vilazodone is an inhibitor of ST (serotonin transporter and uptake) (IC50 = 0.5 nM) and SR-1A activator (partial agonist) (IC50 = 0.2 nM; IA = ~60-70%).

Vildagliptin (LAF-237; NVP-LAF 237) inhibits DPP-4 with IC50 of 2.3 nM.

Vinorelbine is a semi-synthetic Vinca alkaloid which is currently used in treatment of different cancer types mainly advanced breast cancer (ABC) and advanced/metastatic non-small cell lung cancer (NSCLC). Vinorelbine-loaded SSM can be developed as a new,

Vinpocetine (Ethyl apovincaminate) is a synthetic derivative of the vinca alkaloid vincamine, selectively inhibits PDE1 in isolated rabbit aorta with IC50 of 21 uM.

VinSpinIn is a potent, cell active chemical probe for the Spin family protein with Kd of 10-130 nM for across the family, displays >300-fold selectivity over a panel of methyltransferases.

VIS351 (VIS-351) is a potent activator of the immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated function of the IDO1 enzyme with Kd of 1.9 uM.

Vitamin B12 is a water-soluble vitamin with roles in brain and nervous system functioning and blood formation through regulation of DNA synthesis, cellular metabolism, fatty acid metabolism, and amino acid metabolism.

VK-1727 (VK1727) is a small-molecule inhibitor of the DNA binding activity of EBNA1 (Epstein-Barr nuclear antigen1).

VK-1850 (VK1850) is a small-molecule inhibitor of the DNA binding activity of EBNA1 (Epstein-Barr nuclear antigen1).

VK4-116 is a novel potent, highly selective dopamine D3 receptor (D3R) antagonist with Ki of 6.8 nM, displays >1,000-fold selectivity over D2R.

VL285 is a potent VHL ligand, degrading HaloTag7 fusion proteins.

VNRX-5133 is a highly potent and specific beta-lactamase inhibitor, for use in combination with a licensed beta-lactam antibiotic.

Voxilaprevir (GS-9857) is a potent HCV NS3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir for treatment of HCV infection.

VP-14637 (MDT-637) is a novel RSV fusion inhibitor with EC50 of 1.4 nM, reduces RSV replication by inhibition of the F-protein function.

VPC 14449 is a potent and selective androgen receptor DNA-binding domain (AR-DBD) inhibitor with IC50 of 0.34 uM, without affecting AR protein expression.

VPC-18005 (VPC18005) is a novel small molecule ERG (ETS-related gene) antagonist that inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, disrupts the ERG binding to DNA (Kd=250 uM).

VPC-80051 (VPC80051) is the first small molecule inhibitor of hnRNP A1 splicing activity, targets RNA-binding domain (RBD) of hnRNP A1.

VS-5584 (SB2343) is a potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

VS-II-173 is a highly potent Pim1 and Pim3 inhibitor with IC50 of 70 and 20 nM respectively, and a potent and selective inducer of AML cell death (IC50=5.5 uM, Molm-13 cell).

VT-1161 is a potent, highly-selective, and oral fungal CYP51 inhibitor with Kd of ≤ 39 nM.

VT-1598 is a potent, high-affinity, oral inhibitor of fungal sterol 14α-demethylase (CYP51B) with Kd of 13 nM.

VTI-1002 is a potent and specific inhibitor of human (K i = 4.4 ± 2.0 nM) and murine (IC 50 = 179 ± 18 nM) GzmB, with minimal activity (IC 50 > 300 nM) against Cathepsin-G, neutrophil elastase and caspases (−3, −4, −5, −7, −8 and −9). In addition to its high specificity for GzmB, VTI-1002 is retained in murine skin for up to 24 hours and exhibits minimal toxicity in vivo with no observed adverse effects after 30 consecutive days of systemic administration in mice [31]. VTI-1002-mediated GzmB inhibition was first reported to augment type I collagen fibrillogenesis and improve tensile strength in a murine diabetic burn model, notably by preventing decorin cleavage and dermal fibrillar collagen network disorganization.

VU 0240551 is a potent, selecticve inhibitor of the neuronal K-Cl cotransporter KCC2 with IC50 of 568 nM in K+ uptake assay in KCC2-overexpressing cells.

VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM.

VU 0650786 (VU0650786, VU-0650786) is a potent and selective, CNS penetrant mGlu3 negative allosteric modulator with IC50 of 392 nM, with no significant activity against other mGlus (IC50>10 uM).

VU 10010 is a selective, allosteric potentiator of M4 mAChR (EC50=33 and 0.7 nM for ACh in the absence and presence of VU10010 respectively), has no activity at other mAChR subtypes.

VU 6008667 is a potent, highly selective M5 negative allosteric modulator with IC50 of 1.2 uM.

VU0134992 (VU 0134992) is a potent, selective blocker of the inward rectifier potassium channel Kir4.1 (KCNJ10) with IC50 of 0.97 uM in whole-cell patch clamp electrophysiology assays; displays 9-fold selectivity for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 uM) at -120 mV; VU0134992 is greater than 30-fold selective for Kir4.1 over Kir1.1, Kir2.1, and Kir2.2, is weakly active toward Kir2.3, Kir6.2/SUR1, and Kir7.1, and is equally active toward Kir3.1/3.2, Kir3.1/3.4, and Kir4.2 in Tl+ flux assays; causes dose-dependent diuresis, natriuresis, and kaliuresis in rats after oral treatment; VU0134992 represents the first in vivo-active tool compound for probing the therapeutic potential of Kir4.1 as a novel diuretic target for the treatment of hypertension.

VU0152099 is a potent, selective, CNS-penetrant positive allosteric modulator of M4 mAChR with EC50 of 403 nM.

VU0155041 is a Potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively).

VU0155069 is a potent, selective phospholipase D1 (PLD1) inhibitor with IC50 of 46 nM, 20-fold selectivity over PLD2 (IC50=933 nM).

VU0155094 is a potent, selective pan-Group III mGlu positive allosteric modulator with IC50 of 3.43/1.5/0.93 uM for mGlu8/7/4, respectively.

VU0357121 is a novel allosteric modulator of mGlu5 with EC50 of 33 nM.

VU0361737 is inactive at mGlu1, mGlu2, mGlu3, mGlu6 and mGlu7 receptors and displays weak activity at mGlu5 and mGlu8 receptors.

VU0400195 (ML 182) is a potent, selective, brain penetrant and orally active positive allosteric modulator of mGluR4 with EC50 of 291 nM and 376 nM for human and rat mGluR4, respectively.

VU0410425 is a potent, selective negative allosteric modulator of rat mGluR1 with IC50 of 140 nM, inactive at human mGluR1 (IC50>30 uM)..

VU0422288 is a potent, selective, CNS-penetrant pan-Group III mGlu positive allosteric modulator with IC50 of 110/146/130 nM for mGlu8/7/4, respectively, displays >30-fold selectivity over groups I and II mGlus (mGlu1/2/3/5/6)..

VU0424238 is a novel and selective mGlu5 antagonist with an IC50 value of 11 nM (rat) and an IC50 value of 14 nM (human). VU0424238 has an acceptable CNS penetration.

VU0466551 (VU-0466551) is a potent, selective, small-molecule GIRK activator with EC50 of 70.6 nM (GIRK1/2 channels).

VU0467485 (VU-0467485, AZ13713945) is potent, selective, and orally bioavailable muscarinic acetylcholine receptor 4 (M4) positive allosteric modulator with EC50 of 78.8 nM (hM4).

VU0481443 (ML380) is a potent, selective and CNS penetrant M5 positive allosteric modulator (PAM) with EC50 of 190 nM for hM5.

VU0486846 is a novel potent, highly selective M1 mAChR positive allosteric modulation (PAM) with EC50 of 0.31 uM.

VU0529331 (VU 0529331) is the first synthetic small molecule activator of non-GIRK1-containing GIRK (non-GIRK1/X) channels that can specifically modulate the activity of GIRK1-containing GIRK channels..

VU0810464 (VU 0810464, VU464) is a selective neuronal GIRK channels activator, displays nanomolar potency for GIRK1/2 (EC50=163 nM) and improved brain penetration.

VU-29 (DPAP) is a potent, selective and allosteric potentiator of rat mGlu5 receptor with EC50 of 9 nM, displays >50-fold selectivity over mGlu1 and mGlu2 receptor (EC50=557 nM and 1.51 uM).

VU6001221 is a potent choline transporter (CHT) inhibitor with IC50 of 270 nM.